Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 in Healthy Subjects

Trial Profile

Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2019

At a glance

  • Drugs XEN 901 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 06 Jan 2019 Results published in the Media Release.
    • 29 Aug 2018 According to a Xenon Pharmaceuticals media release, this trial continues to make progress with dosing in MAD cohorts underway, and, to date, the data are consistent with the promising interim results presented in May 2018.
    • 29 Aug 2018 According to a Xenon Pharmaceuticals media release, Xenon, along with its collaborators at King College, are exploring the use of the TMS assay in a small subset of a subjects in this ongoing XEN901 phase 1 clinical trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top